Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity
REVANCE THERAP (NASDAQ: RVNC) Delayed: 3.65 --0 (-0%)
Previous Close $3.65    52 Week High $41.12 
Open $3.65    52 Week Low $12.35 
Day High $3.65    P/E N/A 
Day Low $3.65    EPS $-27.14 
Volume 9,900